- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07320469
Efficacy of Inspiratory Muscle Trainers on Patients With Obesity and LowBack Pain
Efficacy of Inspiratory Muscle Trainer on Respiratory Functions Exercise Capacity and Pain Intensity in Adults With Obesity and Mechanical Low Back Pain. A Randomized Clinical Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of this study is to investigate the effects of inspiratory muscle trainers on respiratory function, exercise capacity, pain intensity, and functional disability in patients with obesity and MLBP. If a significant improvement is found, IMT could be added to the guidelines for exercise prescriptions for obese patients with MLBP. Therefore, this study might provide evidence-based findings to guide clinical decision-making and empower clinicians and healthcare organizations to incorporate IMT into exercise prescription guidelines for obese patients with MLBP. By integrating IMT into guidelines, this study might enhance rehabilitation strategies for obese patients with MLBP.
Hypothesis
- Null Hypothesis: the addition of IMT to aerobic exercise does not result in significant differences in respiratory functions, exercise capacity, pain intensity, and functional disability in patients with obesity and mechanical low back pain.
- Alternative Hypothesis: the addition of IMT to aerobic exercise results in significant differences in respiratory functions, exercise capacity, pain intensity, and functional disability in patients with obesity and mechanical low back pain.
Objectives of the study:
- To assess the effects of PowerBreathIMT on pulmonary function tests and maximum inspiratory pressure in patients with obesity and mechanical low back pain.
- To assess the effects of PowerBreathIMT on exercise capacity, pain intensity and functional disability in patients with obesity and mechanical low back pain.
Expected Results The addition of IMT to aerobic exercise results in significant differences in respiratory functions, exercise capacity, pain intensity, and functional disability in patients with obesity and mechanical low back pain.
Material and methods:
o Study setting: The current study will be conducted at King Fahad Hospital of the University, Al Khobar, Saudi Arabia. All participants will be recruited from the orthopedic and neurological clinics after confirming their diagnosis (they suffer from mechanical low back pain & exclude the existence of other causes for back pain). All measurements will be done at the Pulmonary Function Test Lab in the previous week of our intervention and in the next week after the end of our intervention. Participants will practice the supervised sessions at the hospital three times per week for six weeks. During supervised sessions, all participants will follow a dietary regime and perform aerobic exercise and resistance training in addition to IMT training.
NB: Home program: All participants of both groups will also perform aerobic exercise and IMT training two sessions per week at home. The participants from both groups will receive detailed instructions to guide them in performing home sessions. A follow-up with them will be through WhatsApp and Zoom, and I will call them every other day to check their performance. The participants will also have logbooks to document aerobic exercise, resistance training, and IMT training at home and to document the adherence and completeness of the training program.
NB: Diet Program: All participants of both groups will follow an individualized diet program.
Sample Size Calculation: Sample size was calculated by using data from a previous study that assessed the significant difference between two independent means (intervention and control groups) with a primary outcome measure of Vital Capacity from a Pulmonary Function Test (mean 1 = 4.28 and mean 2 = 4.07, sigma= 0.2) . The parameters used for the calculation included an alpha level of 0.05 and a power of 0.90. This link was used, which is a valid and reliable tool for calculating sample size when comparing two means. The sample size was 20 participants in each group to find out a significant difference with sufficient power. So, the total sample size will be 40. However, to account for a 20% attrition rate and dropouts, the sample size will be adjusted. The adjusted sample size will be calculated as a total of 48 participants, resulting in approximately 24 participants in each group.
• Ethical considerations: Ethical approval was obtained from the institutional review board of the Dean of Scientific Research at Imam Abdulrahman bin Faisal University. Moreover, approval from the Saudi Food and Drug Administration was obtained. Each patient will sign a consent form to authorize participation. They will be informed that their information and data will be confidential, and the collected data will be published in the future. The participants will be informed that participation is voluntary, and they can withdraw at any time without consequences.
- Recruitment and study population: Participants who meet the inclusion criteria will be recruited from orthopedic and neurologic clinics in the outpatient department of King Fahad Hospital of the University to participate in this study.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maali M Alqahtani, master
- Phone Number: 0568899888
- Email: maalqahtani@iau.edu.sa
Study Contact Backup
- Name: Alsayed Shanab, PhD
- Phone Number: 0555786349
- Email: aashanb@iau.edu.sa
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males and females
- Aged between 20 and 50 years
- Obese and experiencing mechanical low back pain (MLBP)
- A body mass index (BMI) between 30 and 40 kg/m²
- low back pain for more than 12 weeks, with pain localized to the lumbar region - A pain score greater than 3 but less than 7 on the Numeric Pain Rating Scale (NPRS).
- Low back pain will be screened using the Mechanical and Inflammatory Low Back Pain (MIL) Index.
- Stable and controlled medical conditions
Exclusion Criteria:
- Medically unstable
- Severe spinal pathology, e.g., infection, tumor, arthritis, inflammation, spine deformity, advanced neurologic diseases, head or spinal surgeries, rheumatic diseases, and respiratory muscle paralysis
- Acute inflammation of the musculoskeletal system
- Pregnancy
- Unable to follow instructions, e.g., those with learning difficulties
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental group : IMT with 40%Of MIP +walking +resisancee training
Experimental Group: Twenty-four participants will practice aerobic exercise (30 minutes of walking at 40-60% of HRmax) and resistance training in addition to IMT (starting resistance level of 40%) three times a week for six weeks. Home program: All participants of both groups will also perform different exercises, including aerobic, resistive, and IMT training two times per week at home. The participants from both groups will receive detailed instructions to guide them in performing home sessions. Follow up with them through WhatsApp and Zoom, and call them every other day to check their performance and encourage them. Participants will also have logbooks for documentation and to count the adherence and compliance. |
Inspiratory muscle trainer: The POWER breath device has a variable resistance, which can be adjusted by a calibrated spring.
The initial resistance training level will be adjusted at 0% resistance for the control group and 40% of MIP for the experimental group.
The participants will be instructed to use the device twice daily (two times per day, in the hospital under supervision, 30 breaths in each session) for three days a week for 6 weeks, with periods of rest, especially if the patient feels dizzy or fatigued.
|
|
Placebo Comparator: Control group: IMT with 0% of MIP +walking +resistance training
Twenty-four participants will practice aerobic exercise (30 minutes of walking at 40-60% of HRmax) and resistance training in addition to IMT (starting resistance level of 0%) three times a week for six weeks. Home program: All participants of both groups will also perform different exercises, including aerobic, resistive, and IMT training two times per week at home. The participants from both groups will receive detailed instructions to guide them in performing home sessions. Follow up with them through WhatsApp and Zoom, and call them every other day to check their performance and encourage them. Participants will also have logbooks for documentation and to count the adherence and compliance. |
Inspiratory muscle trainer: The POWER breath device has a variable resistance, which can be adjusted by a calibrated spring.
The initial resistance training level will be adjusted at 0% resistance for the control group and 40% of MIP for the experimental group.
The participants will be instructed to use the device twice daily (two times per day, in the hospital under supervision, 30 breaths in each session) for three days a week for 6 weeks, with periods of rest, especially if the patient feels dizzy or fatigued.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pulmonary Function Test
Time Frame: 6 weeks
|
a. Pulmonary Function Tests: are essential for assessing lung function and are highly valid and reliable.
Spirometry will be used to assess pulmonary function following standard maneuvers.
|
6 weeks
|
|
Maximal Inspiratory Pressure
Time Frame: 6 weeks
|
b. Maximum Inspiratory Pressure (MIP) is a reliable and valid measure of inspiratory muscle strength, influenced by factors such as age, sex, height, and weight.
It demonstrates good test-retest reliability and strong concurrent validity when compared with reference tests in COPD patients.
It will be measured by cmH₂O.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximal O2 uptake (VO2 max)
Time Frame: 6 weeks
|
a. Maximal O₂ uptake (VO₂ max) is the gold standard for assessing cardiovascular fitness and aerobic capacity, showing excellent validity and reliability.
VO₂ max reflects the efficiency of the cardiovascular and respiratory systems in oxygen delivery and utilization.
It is measured by ml/kg/min.
|
6 weeks
|
|
Pain intensity
Time Frame: 6 weeks
|
Pain intensity will be assessed using the 11-point Numerical Pain Rating Scale (NPRS), ranging from 0 ("no pain") to 10 ("worst imaginable pain").
The NPRS shows excellent reliability and strong validity.
|
6 weeks
|
|
Body composition
Time Frame: 6 weeks
|
Body composition will be measured using a bioelectrical impedance analyzer (BIA), which estimates body composition by measuring the body's impedance to a small electrical current.
By using personal data, the device provides valid and reliable measurements across populations.
The measurement will be by Body Mass Index, which is expressed as KG/M².
BIA assessments will be conducted before and after training to compare changes in body composition.
|
6 weeks
|
|
Oswestry Disability Index (Arabic Version)
Time Frame: 6 weeks
|
The questionnaire will be administered to both groups before and after the intervention.
It is a valid and reliable tool that assesses the impact of back pain on daily activities.
It includes 10 sections covering various life aspects, including pain intensity.
Scores are interpreted as follows: 0-20% = minimal disability, 21-40% = moderate disability, 41-60% = severe disability, and 81-100% = exaggerated symptoms and severe impairment, requiring urgent intervention.
|
6 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Maali M Alqahtani, Master, Imam Andulrahman BinFaisal University
- Study Director: Alsayed M Shanab, PhD, Imam Abdulrahman BinFaisal University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Pathologic Processes
- Nutrition Disorders
- Overnutrition
- Body Weight
- Respiratory Tract Diseases
- Respiration Disorders
- Overweight
- Back Pain
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Pain
- Obesity
- Respiratory Aspiration
- Low Back Pain
Other Study ID Numbers
- IRB-PGS-2025-03-0528
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
Clinical Trials on Inspiratory muscle trainer
-
Wake Forest University Health SciencesCompletedRespiratory Failure | Critically IllUnited States
-
National Taiwan University HospitalCompletedAcute Exacerbation of Chronic Obstructive Pulmonary DiseaseTaiwan
-
University of MichiganNational Multiple Sclerosis SocietyCompletedMultiple SclerosisUnited States
-
University of SalamancaCompleted
-
University of SalamancaUnknownMultiple Sclerosis
-
Boston Children's HospitalCompletedCongenital Heart Disease | Single VentricleUnited States
-
Indonesia UniversityCompletedChronic Obstructive Pulmonary DiseaseIndonesia
-
Cairo UniversityCompletedHypertension | Covid19 | Corona Persistent SymptomsEgypt
-
Cairo UniversityRecruitingGuillain-Barre SyndromeEgypt
-
Cairo UniversityCompletedPostmenopausal Symptoms | AsthmaticEgypt